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Review
Familial combined hypolipidemia due to 
mutations in the ANGPTL3 gene
ANGPTL3 & plasma lipoprotein 
metabolism in mice & humans
ANGPTLs represent a family of secreted glyco­
proteins with high homology to angiopoietins, 
the key regulators of angiogenesis. However, 
ANGPTLs cannot bind the angiopoietin 
receptors (TIE1 and TIE2) specifically expressed 
on endothelial cells [1]. ANGPTLs share two 
common domains with angiopoietins, a coiled­
coil domain at the N­terminal region and a 
fibrinogen­like domain at the C­terminal, 
which are connected by a linker region. Two 
members of the ANGPTL family (ANGPTL3 
and ANGPTL4) have received great attention 
in the last few years due to their effects on 
lipoprotein metabolism in mice and humans 
([2–5] for review). 
The first observation which demonstrated 
a link between ANGPTL3 and lipoprotein 
metabolism was made by Koishi et al. who 
investigated a mouse strain (KK/San or KK/Snk) 
derived from the colony of KK mice characterized 
by obesity, diabetes and hypertriglyceridemia 
[6]. The KK/San mice, despite maintaining the 
phenotype of obesity and diabetes, had a marked 
decrease (>90%) of plasma triglyceride (TG) 
as compared with the original hyperlipidemic 
KK mice. This hypotriglyceridemia was 
associated not only with a reduction in pre­b 
lipoproteins (VLDL), but also in the b­ and 
a­lipoproteins (LDL and HDL, respectively). 
The hypotriglyceridemia of KK/San mice was 
found to be inherited as a recessive trait. Using 
positional cloning, Koishi et al. identified the 
hypolipidemia locus (located in the middle of 
chromosome 4) in the gene encoding ANGPTL3 
[6]. KK/San mice were homozygous for a 4­bp 
insertion in exon 7, which introduced a stop 
codon at position 347, predicted to result in 
the truncation of the ANGPTL3 protein and 
expected to be associated with a complete 
ANGPTL3 deficiency. Koishi et al. also showed 
that treatment with recombinant ANGPTL3 
or adenovirus­mediated overproduction of 
ANGPTL3­elevated plasma TG and total 
cholesterol (TC) [6]. Subsequent studies showed 
that ANGPTL3 increased VLDL­TG levels by 
inhibiting lipoprotein lipase (LPL) activity [7,8] 
and that the plasma TG level was markedly 
reduced in ANGPTL3 null mice (Angptl3-/-) [9].
An extensive investigation of Angptl3-/- mice 
fed a normal diet or a high­fat diet revealed a 
great reduction of plasma lipid levels (73 and 
55% in TG and 40 and 45% in TC, respectively) 
[10]. This confirmed that complete ANGPTL3 
deficiency had a profound effect not only on 
TG­containing lipoproteins (VLDL), but also 
on cholesterol­carrying lipoproteins such as 
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LDL and HDL. Postheparin LPL and hepatic 
lipase activities were significantly increased in 
Angptl3-/- (1.57­ and 1.42­fold, respectively). 
Furthermore, in vivo hepatic TG secretion rate 
in Angptl3-/- injected with Triton WR1339 
was found to be lower than in control mice, 
although the difference did not reach the level 
of significance [10]. In conclusion, Angptl3-/- had 
a combined hypolipidemia phenotype associated 
with enhanced LPL and hepatic lipase activity 
[10]. Unfortunately, this study did not provide 
data on the plasma lipids in Angtpl3+/- mice.
In humans, the ANGPTL3 gene is located on 
chromosome 1 (1p31.1­p22.3), where it encodes 
a 460 amino acid protein that is produced 
exclusively by the liver. ANGPTL3 consists 
of a signal peptide, an N­terminal segment 
containing coiled­coil domains and a C­terminal 
fibrinogen­like domain, which are connected 
with a linker region. ANGPTL3 is susceptible 
to proteolytic cleavage at specific sites in the 
interlinker region by the action of several hepatic 
pro­protein convertases (PCs): Furin, PCSK2, 
PCSK4, PACE4, PCSK5 and PCSK7 (Figure 1) 
[2]. The cleaved N­terminal of ANGPTL3 is 
more efficient at inhibiting LPL than full­length 
ANGPTL3 and the deletion of the N­segment 
leads to the total loss of the inhibitory activity 
of the protein [7,8]. Recently, a specific amino 
acid sequence of the N­terminal of ANGPTL3 
has been identified as the domain that mediates 
the interaction between ANGPTL3 and LPL, 
and the subsequent inactivation of LPL. This 
region corresponds to amino acids E32–H55 
(Figure 1); a mouse antibody against this region 
inhibited the binding of ANGPTL3 to LPL and 
neutralized ANGPTL3­mediated inhibition 
of LPL [11]. The mechanism underlying the 
inhibition of LPL by ANGPTL3 appears to 
be manifold. By using enzyme kinetic ana lysis 
with purified recombinant proteins, Shan et al. 
found that ANGPTL3 reduced LPL catalytic 
activity (i.e., the activity of the dimeric form of 
LPL), but did not significantly alter the LPL self­
inactivation rate (i.e., the process leading to the 
irreversible disruption of the dimeric form of the 
enzyme) [12]. An alternative or complementary 
mechanism of inhibition of LPL has emerged 
from in vitro cell­based studies that investigated 
the interactions among ANGPTL3, PCs and 
LPL. These studies demonstrated that LPL 
is inactivated by cleavage by PCs and that 
ANGPTL3 is a potent inhibitor of LPL in 
physiological concentrations and in the presence 
of cells by enhancing the cleavage of LPL by PCs 
such as furin and PACE­4.
By enhancing LPL cleavage, ANGPTL3 
dissociates LPL from the cell surface, thus 
inhibiting both the catalytic and noncatalytic 
functions of this enzyme [13]. One interesting 
question is whether ANGPTL3 exerts its 
inhibitory effect on the LPL that is bound to 
TG­rich lipoproteins (chylomicrons and VLDL) 
or to GPIHBP1, the platform for LPL­processing 
of TG­rich lipoproteins [14]. Recently, Nilsson 
et al. have investigated the effects of some 
lipoproteins (chylomicrons, VLDL and LDL) on 
the inactivation of LPL in vitro by the human 
N­terminal fragment of ANGPTL3 [15]. They 
found that the presence of chylomicrons and 
VLDL protected LPL against inactivation by 
ANGPTL3. On the other hand, it has been 
shown that ANGPTL3 inhibits heparin­bound 
LPL but not LPL bound to GPIHBP1 [16]. So 
it appears that ANGPTL3 exerts its inhibitory 
effect predominantly on nonstablized LPL 
(Figure 2).
In addition to its role in the inhibition 
of LPL, ANGPTL3 is capable of inhibiting 
endothelial lipase (EL). Shimamura et al. found 
that Angptl3-/- had low plasma HDL cholesterol 
(HDL­C) levels accompanied by increased 
phospholipase activity [17], indicating that the 
activity of EL (which acts as a phospholipase) is 
elevated in these mice and that ANGPTL3 acts 
as an endogenous inhibitor of EL. Interestingly, 
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Figure 1. structure of human ANGPTL3 protein. The protein contains a SP 
followed by an a-helical region to form a CCD at the N-terminus and a FBG at the 
C-terminus. These domains are separated by a linker region that is cleaved by the 
action of PPCs. Some missense mutations found in hypolipidemic subjects, reported 
to prevent the secretion or affect the function of ANGPTL3 in vitro, are indicated 
above the protein structure. Mutations producing truncated proteins or single amino 
acid deletions are shown below the protein structure. 
CCD: Coiled-coil domain; FBG: Fibrinogen globular domain; PPC: Pro-protein 
convertase; SP: Signal peptide.
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the inhibition of PCs, which are responsible 
for the activation of ANGPTL3 (as previously 
mentioned) attenuated the inhibitory effect of 
ANGPTL3 on EL [18].
Thus, PCs that regulate EL activity directly 
through the cleavage of the EL protein [19] also 
affect this enzyme indirectly by modulating the 
ANGPTL3 level in the liver. In this context, 
the changes of HDL, seen in Angptl3-/- mice 
due to unrestrained EL activity, are expected 
to bear some similarity with those observed in 
mice overexpressing EL. Indeed, overexpression 
of EL in mice by a recombinant adenovirus 
dramatically lowered HDL­C and ApoA­I [20].
Activation of ANGPTL3 by ANGPTL8, 
a new member of the ANGPTL family
Recently, the activity of ANGPTL3 on plasma 
lipoprotein has been linked to a new member 
of the ANGPTL family, designated ANGPTL8 
[21], which had been previously designated with 
various terms (TD26, hepatocellular carcinoma­
associated gene, C19orf80, refeeding­induced 
fat and liver or lipasin) [22,23]. Zhang was the 
first to show that lipasin (ANGPTL8) shared 
homology with the N­terminal domain of 
ANGPTL3, which is needed for inhibition of 
LPL; recombinant human lipasin inhibited LPL 
in vitro and adenovirus­mediated injection of 
lipasin increased mouse serum TGs [23].
The role of ANGPTL8 has been extensively 
investigated by Quagliarini et al. who demon­
strated that ANGPTL8 is a plasma protein whose 
expression is modulated by fasting and refeed­
ing [21]. They found that the expression of human 
ANGPTL8 in the livers of mice was associated with 
a significant increase in plasma levels of TG and 
nonesterified fatty acids (NEFA). By contrast, the 
expression of human ANGPTL3 did not induce 
elevation of TG or NEFA, while the coexpression 
of ANGPTL8 and ANGPTL3 induced a striking 
increase of both TG and NEFA, thus suggesting 
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Figure 2. Model of interactions of ANGPTL3 with lipoprotein lipase and endothelial lipase in peripheral tissues. 
LPL synthezised in adipose tissue is secreted as a homodimer by the action of LMF1 and then transported to the luminal side of the 
capillary endothelial cells by transendocytosis mediated by GPIHBP1. ANGPTL3 binds to unstabilized LPL (i.e., LPL that is not bound to 
chylomicrons/VLDL on the GPIHBP1 molecular platform). ANGPTL3 may induce the reversible inhibition of LPL or the irreversibile 
degradation of LPL by PPCs (PACE4 and Furin). The N-terminal fragment of ANGPTL3 (N-ANGPTL3) cleaved by PPCs and also inhibits EL. 
CHYLOS: Chylomicron; EL: Endothelial lipase; ER: Endoplasmic reticulum; FC: Free cholesterol; HSPG: Heparan sulfate proteoglycan; 
LPL: Lipoprotein lipase; PL: Phospholipid; PPC: Pro-protein convertase; TG: Triglyceride.
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a concerted action of these proteins. In cultured 
hepatocytes, ANGPTL8 expression increased 
the appearance of N­terminal ANGPTL3 in 
the medium, suggesting that ANGPTL8 may 
activate ANGPTL3 by facilitating its cleavage. 
Consistent with this hypothesis, the expression 
of ANGPTL8 in Angptl3­/­ mice failed to pro­
mote hypertriglyceridemia. Therefore, in this 
new scenario, ANGPTL8 would be required to 
ensure full biological activity of ANGPTL3 on 
plasma lipoproteins (Figure 3). It has been pro­
posed that ANGPTL8 activates ANGPTL3 by 
binding to the N­terminal domain of the full­
length ANGPTL3 and promoting its cleavage. 
After cleavage, ANGPTL8 remains bound to 
ANGPTL3 and forms an active complex circu­
lating in plasma (Figure 3) [21]. Thus, ANGPTL8 
acts to increase plasma TG levels and this requires 
the presence of ANGPTL3. This is consistent 
with the observation that Angptl8­/­ mice have 
markedly decreased TG levels compared with 
wild­type mice [24]. 
Plasma levels of ANGPTL3 
& correlation with plasma lipids
Using an antibody sandwich ELISA system, 
Shimamura et al. found that the concentration 
of ANGPTL3 in the plasma of healthy 
Japanese subjects (mean age: 33.6 ± 8.4 years; 
male/female: 45/42) in overnight fasting 
conditions ranged from 50 to 800 ng/ml (mean 
value: 470 ± 122 ng/ml) [17]. Plasma ANGPTL3 
correlated strongly with plasma HDL­C 
(r = 0.500; p < 0.001) and HDL­phospolipid 
levels (r = 0.286; p = 0.007), but not with 
plasma TC or TG levels [17]. Hatsuda et al., 
using a commercially available kit assay, showed 
that in 381 healthy Japanese subjects, the mean 
plasma level of ANGPTL3 was 764 ± 291 ng/ml, 
with no difference between males and females 
[25]. By simple linear regression ana lysis, plasma 
ANGPTL3 levels did not correlate with age, 
BMI or plasma lipid parameters (TC, HDL­C 
and TG), fasting blood glucose, log­transformed 
insulin or the homeostasis model assessment 
of insulin resistance. Robciuc et al., using a 
noncompetitive ELISA assay, found that the 
plasma/serum concentration of ANGTPL3 
was 347.8 ± 159.4 and 388.6 ± 204.1 ng/ml in 
healthy Finnish middle­aged males (n = 125) 
and females (n = 125), respectively [26]. Bivariate 
correlations revealed a positive association 
of serum ANGPTL3 with age (r = 0.292; 
p < 0.001), plasma HDL­C (r = 0.224; p < 0.001) 
and ApoA­I (r = 0.144; p = 0.023), and a 
negative correlation with plasma TG (r = ­0.182; 
p = 0.004). However, the correlation with 
plasma TG was completely lost when HDL­C 
and ApoA­I were used as control variables [26]. 
A strong correlation between plasma ANGPTL3 
and HDL­C was also documented by Moon et al. 
in a group of Japanese subjects that also included 
individuals with hyperalphalipoproteinemia 
(HDL­C level >90 mg/dl; >2.33 mmol/l) [27]. 
Overall, it seems that that there is a positive 
correlation between plasma ANGPTL3 and 
plasma HDL in accordance with the studies in 
mice [17]. This relationship is indirectly supported 
by the observation that among Japanese 
individuals with elevated HDL­C (>90 mg/dl; 
>2.33 mmol/l), the prevalence of high plasma 
ANGTPL3 levels (>362 ng/ml) was found to be 
tenfold higher (44%) compared with that (4.5%) 
of low plasma CETP (<0.39 µg/ml; normal 
values 1.29 ± 0.90 µg/ml), a condition known 
to be associated with elevated plasma HDL­C 
[27]. The plasma levels of ANGPTL3 have also 
been associated with preclinical atherosclerosis. 
Hatsuda et al. found a positive association 
between plasma ANGPTL3 and carotid and 
femoral artery intima­medial thickness in 381 
healthy volunteers after adjustment for other 
cardiovascular risk factors such as age, blood 
pressure and plasma glucose and lipid levels [25]. 
ANGPTL3 gene variants & plasma 
lipids in population studies
Recently, several genetic approaches have 
unequivocally proved the key role of ANGPTL3 
in human lipoprotein metabolism. Genome­
wide association studies (GWAS) have been 
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Figure 3. Model of interaction of ANGPTL8 with ANGPTL3 in hepatocytes. 
ANGPTL8–ANGPTL3 interaction facilitates the proteolytic cleavage of ANGPTL3. 
ANGPTL8 remains attached to the N-terminal fragment of ANGPTL3, forming a 
complex that is secreted. Both the ANGPTL3–ANGPTL8 complex and the free 
N-terminal fragment of ANGPTL3 inhibit LPL. 
LPL: Lipoprotein lipase. 
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used as unbiased tools to identify novel genes 
asso ciated with lipid traits in a population. 
Among the loci associated with plasma TG, 
a locus was identified on chromosome 1p31 
near the ANGPTL3 gene [28]. The intergenic 
single nucleotide polymorphism rs12130333 
(minor allele frequency [MAF] = 0.22) was 
associated with a reduction in plasma TG [28]. 
This observation was confirmed in a subsequent 
study and a meta­ana lysis [29], which showed 
that the rare allele of another single nucleotide 
polymorphism (rs2131925, MAF = 0.32) near 
the ANGPTL3 gene had an effect size on plasma 
TG of ­4.95 mg/dl.
GWAS prompted the population­based 
resequencing of the coding region of the 
ANGPTL3 gene, which led to the identification 
of multiple rare nonsynonymous (NS) sequence 
variants that were associated with reduced plasma 
TG levels in individuals of the DHS and ARIC 
study [30]. A total of 35 rare NS amino acid 
variants were identified in ANGTPL3 and an 
excess of these variants (14 vs 5; p = 0.064) were 
found in the lower quartile of plasma TG levels 
(Tables 1 & 2). All sequence variants expected to 
be loss­of­function (LOF) alleles (which impaired 
the secretion of the mutant ANGPTL3 from the 
cells in vitro or produced truncated ANGPTL3 
proteins) were in the lower quartile of TG levels of 
the reference population. In addition, the variant 
Met259Thr (M259T), a relatively frequent NS 
variant in African–Americans (MAF = 0.05) was 
found to be associated with significantly lower 
plasma TG, with a clear gene­dosage effect. In vitro 
studies indicated that the ANGPTL3–259T 
variant, as well as some other rare NS variants 
found in the low TG group, failed to suppress 
LPL activity in vitro, as compared with the wild 
type ANGPTL3 [30]. Interestingly, the rare LOF 
variants in ANGPTL3, found in individuals 
with low plasma TG, were not associated 
with significant changes in the levels of LDL 
cholesterol (LDL­C) and HDL­C. No changes 
of other metabolic parameters were observed in 
carriers of common or rare LOF variants, apart 
from a low plasma level of blood glucose found in 
carriers of the DHS population. Regrettably, no 
data were given on the plasma level of ANGPTL3 
in carriers of these variants [30]. 
ANGPTL3 & familial combined 
hypolipidemia
The compelling evidence of the role of LOF 
mutations of ANGPTL3 as the cause of hypo­
lipidemia in humans emerged from the genomic 
investigation of a large family, originally 
classified as familial hypobetalipoproteinemia 
(FHBL) by Schonfeld’s group in 1998 [31]. FHBL 
includes a heterogeneous group of autosomal 
codominant disorders characterized by plasma 
levels of TC, LDL­C and ApoB below the fifth 
percentile of the population distribution [32]. 
Approximately 50% of FHBL subjects identified 
in clinical settings are carriers of mutations in 
the APOB gene (APOB­linked FHBL), which 
either prevent the complete translation of APOB 
mRNA (resulting in the production of truncated 
ApoBs of various length) or result in missense 
mutations that cause an accelerated intracellular 
degradation of the mutant APOB [32]. A total 
of 2% of FHBL subjects are carriers of LOF 
mutations in the PCSK9 gene (PCSK9­linked 
FHBL), while in others, the genes responsible for 
the disorder are unknown (‘orphan FHBL’) [32]. 
In the FHBL family described by Schonfeld’s 
group (indicated as family ‘F’), the APOB 
gene had been excluded by cosegregation 
ana lysis [31]. By using the strategy of exome 
sequencing, Musunuru et al. demonstrated 
that in this family, four hypocholesterolemic 
siblings were compound heterozygotes for two 
LOF mutations of ANGPTL3 (p.E129*/p.S17*), 
which are expected to cause a complete 
deficiency of ANGPTL3 (Table 2 & Figure 1) [33]. 
Interestingly, these subjects, besides extremely 
low levels of TC and LDL­C (1.41 ± 0.07 and 
0.84 ± 0.09 mmol/l, respectively), had very 
low levels of TG and HDL­C (0.23 ± 0.03 
and 0.46 ± 0.07 mmol/l, respectively). The 
discovery of this lipid disorder, designated 
familial combined hypolipidemia, paved the 
way to the resequencing of the ANGPTL3 
gene in other putative FHBL subjects with a 
combined hypolipidemia phenotype, in whom 
no mutations in APOB or PCSK9 genes had 
been identified. The present authors resequenced 
the ANGPTL3 gene in four individuals 
(belonging to three kindreds) with a plasma 
lipid profile comparable to that of family ‘F’ 
(TC: 1.76 ± 0.30; TG: 0.49 ± 0.13; LDL­C: 
0.97 ± 0.16; HDL­C: 0.56 ± 0.20 mmol/l) and 
found that they were either homozygotes or 
compound heterozygotes for LOF mutations 
predicted to produce truncated ANGPTL3 
proteins (p.G400Vfs*5, p.I19Lfs*22/p.N147*) 
(Table 2 & Figure 1) [34]. Martín­Campos 
et al. resequenced the ANGPTL3 gene in 
three hypocholesterolemic individuals (TC: 
1.65 ± 0.36; LDL­C: 1.12 ± 0.27; HDL­C: 
0.39 ± 0.07; TG: 0.30 ± 0.05 mmol/l) belonging 
Familial combined hypolipidemia due to mutations in the ANGPTL3 gene | Review
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to two Spanish families with FHBL not linked 
to the APOB gene [35]. These individuals were 
found to be homozygotes for a 5­bp deletion 
resulting in a truncated ANGPTL3 protein 
(p.N121K*3) (Table 2 & Figure 1). More recently, 
Minicocci et al. resequenced the ANGPTL3 
gene in a cluster of FHBL families identified 
in a small town in Central Italy and apparently 
not linked to APOB gene [36]. Overall, the 
ANGPTL3 gene was resequenced in nine 
index cases (plasma LDL­C <fifth percentile), 
28 first­degree relatives, 11 second­degree 
relatives and four spouses. This survey led to 
the identification of six homoygotes and 24 
heterozygotes for a 2­bp change at nucleotides 
50–51 of exon 1 (c.50 CC>GA), introducing 
a premature termination (p.S17*)  (Table 2 & 
Figure 1) [36]. The plasma lipid profile found in 
the homoyzgotes (TC: 2.34 ± 0.33; LDL­C: 
1.24 ± 0.40; HDL­C: 0.89 ± 0.20;  TG: 
0.43 ± 0.13 mmol/l; ApoB: 0.48 ± 0.10; ApoA­I: 
0.85 ± 0.13 g/l) was consistent with a familial 
combined hypolipidemia phenotype, even 
though, on average, the values of TC, LDL­C 
and HDL­C were higher than those found in 
carriers of two LOF alleles belonging to the other 
kindreds investigated so far [33–35].
Finally, Noto et al. addressed the question 
of the impact of ANGPTL3 mutations as the 
cause of a combined hypolipidemia phenotype 
in subjects with the clinical diagnosis of putative 
FHBL [37]. From a large cohort of putative FHBL 
subjects (390 Italians and 523 Americans) they 
selected 78 individuals who presented with a 
combined hypolipidemia phenotype, defined 
by stringent criteria (i.e., TC <second percentile 
and HDL­C <second decile of the populations) 
based on the lipid profile of the four carriers of 
Table 1. ANGPTL3 missense mutations and their predicted effects in silico.
exon cdNA Protein PolyPhen-2† sIFT‡ Mutation 
testing
remark ref.
Pro-
protein
Mature Hum div 
damaging
Hum var 
damaging
Human 
protein
BLink
1 c.121 G>A p.D41N D22N Possibly Possibly Tolerated Damaging Disease-causing HIS, high TG [30]
1 c.167 G>T p.G56V G37V Probably Probably Tolerated Damaging Disease-causing IT, low LDL-C 
and HDL-C
[37]
1 c.188 A>C p.K63T K44T Probably Probably Tolerated Damaging Disease-causing AA, defective 
LPL inhibition
[30]
1 c.214 T>C p.F72L F53L Possibly Benign Tolerated Tolerated Disease-causing HIS, high TG [30]
1 c.272 A>G p.E91G E72G Probably Possibly Tolerated Tolerated Disease-causing AA, defective 
LPL inhibition
[30]
1 c.292 G>A p.E98K E79K Benign Benign Tolerated Tolerated Disease-causing HIS, high TG [30]
1 c.392 A>C p.K131T K112T Probably Probably Tolerated Tolerated Disease-causing EA, high TG [30]
1 c.490 C>T p.L164F L145F Possibly Benign Tolerated Tolerated Disease-causing AA, defective 
LPL inhibition
[30]
2 c.518 A>G p.N173S N154S Benign Benign Tolerated Tolerated Nonpathogenic AA, defective 
LPL inhibition
[30]
4 c.776 T>C p.M259T M240T Benign Benign Tolerated Damaging Nonpathogenic AA, SNP [30]
5 c.863 G>A p.R288Q R269Q Probably Probably Damaging Damaging Disease-causing EA, ANGPTL3 
secretion ↓
[30]
5 c.874 T>C p.S292P S273P Probably Possibly Damaging Damaging Disease-causing AA, ANGPTL3 
secretion ↓
[30]
5 c.883 T>C p.F295L F276L Probably Probably Damaging Damaging Disease-causing IT, low LDL-C 
and HDL-C
[37]
6 c.995 G>A p.R332Q R313Q Probably Probably Tolerated Tolerated Disease-causing IT, low LDL-C 
and HDL-C
[37]
6 c.1123 G>A p.E375K E356K Possibly Benign Tolerated Tolerated Disease-causing EA, ANGPTL3 
secretion ↓
[30]
7 c.1250 A>G p.Y417C Y398C Probably Probably Damaging Damaging Disease-causing AA, ANGTL3 
secretion ↓
[30]
7 c.1283 G>T p.R428M R409M Probably Probably Tolerated Tolerated Disease-causing EA, high TG [30]
†Please see [101] for more details.
‡Please see [102] for more details.
AA: African–American; EA: European–American; HDL‑C: HDL cholesterol; HIS: Hispanic; IT: Italian; LDL‑C: LDL cholesterol; LPL: Lipoprotein lipase; SNP: Single 
nucleotide polymorphism; TG: Triglyceride.
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two mutant alleles in family ‘F’ [33]. The ana­
lysis of APOB and ANGPTL3 genes revealed 
that none of these subjects had mutations in the 
APOB gene, while eight of them were carriers of 
the rare ANGPTL3 mutation (four carriers of two 
mutant alleles and four carriers of one mutant 
allele). The mutations resulted in either truncated 
proteins or single rare nonconservative amino 
acid substitutions expected to be deleterious for 
ANGPTL3 function (Tables 1 & 2 & Figure 1). In 
this study, the plasma lipid profile of carriers of 
two mutant ANGPTL3 alleles (TC: 1.58 ± 0.36; 
LDL­C: 0.90 ± 0.34; HDL­C: 0.46 ± 0.15; TG: 
0.45 ± 0.28 mmol/l) was fairly similar to that 
found in other subjects with familial combined 
hypolipidemia [33–35].
While these studies convincingly demonstrate 
that the presence of two LOF alleles of ANGPTL3 
is associated with the combined hypolipidemia 
phenotype, the features of the lipid phenotype 
in carriers of one LOF allele are not yet clearly 
defined. In the original family ‘F’, reinvestigated 
by Musurunu et al. [33], the carriers of one mutant 
allele were found to have values of LDL­C and 
TG intermediate between those of the carriers of 
two mutant alleles and the noncarrier relatives. In 
sharp contrast, the levels of HDL­C were similar 
to those found in noncarriers, thus suggesting the 
concept that the low LDL­C and TG phenotype 
was transmitted as a codominant trait while the 
low HDL­C level was transmitted as a recessive 
trait [33]. However, at first sight, the results of the 
other studies do not support this contention [34–37]. 
The plasma LDL­C and TG levels in carriers of 
one mutant allele of the Italian kindreds or the 
Spanish kindreds were not significantly different 
from noncarriers [34,35]. On the other hand, 
Minicocci et al., who investigated a large number 
of carriers of the LOF allele p.S17* found that these 
individuals had lower TC and HDL­C levels than 
noncarriers [36]. Finally, 12 heterozygous carriers 
of frameshift mutations (leading to premature 
truncation of the ANGPTL3 protein) found that 
the participants of the DHS trial had significantly 
lower plasma levels of LDL­C than noncarriers 
(median 2.00 mmol/l vs median 2.68 mmol/l 
in noncarriers; p = 0.03). They also showed 
a reduction in plasma TG levels of borderline 
significance (median 0.81 vs 1.08 mmol/l; 
p = 0.08) [33]. 
To clarify this issue, the present authors 
tried to compare the plasma lipid profiles of 
the 94 heterozygous carriers of LOF mutations 
reported so far with those of 45 noncarrier family 
members [33–37]. This comparison showed that 
heterozygotes had significantly lower levels of TC, 
LDL­C and TG, but not significantly reduced 
levels of HDL­C compared with noncarrier 
family members (Table 3 & Figure 4). Although 
more extensive studies are required, the result 
of this comparison would be consistent with a 
codominant transmission of the low LDL­C/TG 
trait and a recessive transmission for the low 
HDL­C trait.
Table 2. ANGPTL3 nonsense and frameshift mutations.
exon cdNA† Pro-protein† Previously reported as ethnic background Ho (n) CHe (n) He (n) ref.
1 c.50–51 CC>GA p.S17* – EA, IT 8 4 60 [33,36,37]
1 c.55delA p.I19Lfs*22 – IT – 3 3 [34]
1 c.247delT p.Y83Mfs*17 Y88fsX99 AA – – 1 [33]
1 c.286_288delGAA p.E96del c.283_284delGAA, E95del IT 1 – 1 [36,37]
1 c.361_365delAACTC p.N121Kfs*3 c.355_360delAACTC, 
E119fsX8
IT – – 1 [37]
1 c.362_363insCTCAT p.K123Sfs*8 c.362insCTCAT, N121fsX9 EA – – 1 [37]
1 c.363_364delCT p.S122Kfs*3 FsS122 IT – – 1 [36]
1 c.363_367delCTCAA p.N121Kfs*3 N121LX2 SP 3 – 4 [35]
1 c.364_367delTCAA p.S122Nfs*6 S122fsX128 AA, EA – – 2 [30,33]
1 c.385G>T p.E129* – EA – 4 6 [33,37]
1 c.439_442delAACT p.N147* N147fsX148 IT, AA, EA 1 4 2 [33,34,37]
2 c.575delA p.Q192Rfs*5 Q192fsX196 AA – – 5 [30,33]
5 c.862_864delCGA p.R288del – AA – – 1 [30]
6 c.1167delA p.G390Dfs*24 K389fsX413 EA – – 1 [33]
IVS6 c.1198 +1G>T p.G400Vfs*5 – IT 1 – 2 [30,34]
7 c.1333_1334insT p.K445Ifs*16 K445fsX459 AA – – 1 [30,33]
†The mutations were designated according to the Human Genome Variation Society, 2011 version [103]. ANGPTL3 protein sequence variants were designated 
according to [104]. 
–: Not applicable; AA: African–American; CHE: Compound heterozygote; EA: European–American; HE: Heterozygote; HO: Homozygote; IT: Italian; SP: Spanish.
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ANGPTL3 gene variants identified in 
humans
Resequencing of the coding sequence of the 
ANGPTL3 gene in population samples and in 
subjects with combined hypolypidemia has led 
to the identification of 17 missense mutations, 
15 mutations resulting in premature termination 
codons (nonsense and frameshift mutations) and 
one splice­site mutation (Tables 1 & 2). Most of 
the missense mutations involved highly conserved 
amino acids and turned out to be possibly 
damaging in silico and eight of them were found 
Table 3. Plasma lipids in ANGPTL3 homozygotes, compound heterozygotes, heterozygotes and noncarrier 
family members reported in the literature.
ANGPTL3: mutations 
[genotype], protein
n Gender 
M/F
Age 
(years)
TC 
(mmol/l)
LdL-C 
(mmol/l)
HdL-C 
(mmol/l)
TG 
(mmol/l)
ref.
HO and CHE
[c.50–51 CC>GA], p.S17* + 
[c.385G>T], p.E129*
4 3/1 34.5 ± 10.6 1.40 ± 0.07 0.84 ± 0.09 0.46 ± 0.07 0.23 ± 0.03 [33]
[c.286_288delGAA] + 
[c.286_288delGAA], p.E96del
1 1/0 36 1.43 1.02 0.25 0.32 [37]
[c.439_442delAACT] + 
[c.439_442delAACT], p.N147* 
1 1/0 19 1.38 0.56 0.43 0.85 [37]
[c.439_442delAACT], p.N147* + 
[c.883 T>C], p.F295L
1 0/1 40 2.13 1.33 0.59 0.44 [37]
[c.1198 +1G>T] + [c.1198 
+1G>T], p.G400Vfs*5 
1 0/1 65 1.87 1.09 0.61 0.37 [34]
[c.55delA], p.I19Lfs*22 + 
[c.439_442delAACT], p.N147*       
3 2/1 65.6 ± 17.0 1.72 ± 0.35 0.93 ± 0.17 0.54 ± 0.24 0.53 ± 0.12 [34]
[c.50–51 CC>GA] + [c.50–51 
CC>GA], p.S17*
8 4/4 64.8 ± 14.2 2.37 ± 0.31 1.35 ± 0.41 0.82 ± 0.22 0.42 ± 0.11 [36]
[c.363_367delCTCAA] + 
[c.363_367delCTCAA], 
p.N121K*3           
3 2/1 30.6 ± 16.2 1.65 ± 0.36 1.12 ± 0.27 0.39 ± 0.07 0.30 ± 0.05 [35]
Overall HO + CHE 22 13/9 50.2 ± 17.4 1.88 ± 0.30 1.10 ± 0.29 0.59 ± 0.17 0.40 ± 0.16 –
HE
[c.50–51 CC>GA], p.S17* 62 28/34 49.1 ± 20.6 4.23 ± 0.79 2.45 ± 0.70 1.38 ± 0.33 0.86 ± 0.43 [33,36]
[c.55delA], p.I19Lfs*22 3 1/2 54.6 ± 34.1 4.34 ± 0.44 2.43 ± 0.14 1.37 ± 0.47 1.13 ± 0.51 [34]
[c.167 G>T], p.G56V 1 1/0 42 2.72 1.64 0.61 1.01 [37]
[c.247delT], p.Y83Mfs*17 1 0/1 47 3.10 1.45 1.24 0.87 [33]
[c.361_365delAACTC], 
p.N121Kfs*3
1 1/0 45 1.49 0.84 0.48 0.30 [37]
[c.362_363insCTCAT], 
p.K123Sfs*8
1 0/1 40 2.33 1.43 0.74 0.29 [37]
[c.363_367delCTCAA], 
p.N121K*3 
4 2/2 35.5 ± 13.2 4.42 ± 0.85 2.84 ± 0.82 1.12 ± 0.20 1.00 ± 0.34 [35]
[c.364_367delTCAA, 
p.S122Nfs*6
2 0/2 33.5 ± 2.1 4.12 ± 1.95 2.58 ± 1.83 1.29 ± 0.14 0.52 ± 0.07 [33]
[c.385G>T], p.E129* 6 3/3 27.8 ± 22.2 3.20 ± 0.57 1.83 ± 0.64 1.13 ± 0.21 0.81 ± 0.28 [33]
[c.439_442delAACT, p.N147* 2 0/2 49.0 ± 9.9 3.59 ± 0.18 2.00 ± 0.01 1.04 ± 0.23 1.18 ± 0.91 [33]
[c.575delA], p.Q192Rfs*5 5 4/1 44.6 ± 9.4 4.17 ± 0.87 2.26 ± 0.73 1.48 ± 0.41 0.92 ± 0.40 [33]
[c.995 G>A], p.R332Q 1 1/0 43 1.54 0.53 0.61 0.82 [37]
[c.1167delA], p.G390Dfs*24 1 1/0 42 3.88 2.17 1.29 0.92 [33]
[c.1198 +1G>T], p.G400Vfs*5 3 1/2 39.0 ± 2.6 4.57 ± 0.14 2.71 ± 0.49 1.46 ± 0.42 0.71 ± 0.16 [34]
[c.1333_1334insT], p.K445Ifs*16 1 1/0 50 4.06 1.96 1.76 0.72 [33]
Overall HE 94 44/50 46.1 ± 19.0 4.05 ± 0.88 2.24 ± 0.73 1.32 ± 0.35 0.84 ± 0.42         –
Noncarrier family members 45 23/22 42.0 ± 19.7 4.81 ± 1.29 2.91 ± 1.13 1.34 ± 0.32 1.22 ± 0.71 [33–36]
HO and CHE vs HE: age and gender distribution (not significant); TC, LDL‑C, HDL‑C and TG (p < 0.0001); HE vs noncarrier family members: age and gender 
distribution (not significant); TC (p < 0.001); LDL‑C (p < 0.001); HDL‑C (not significant) and TG (p < 0.001). 
CHE: Compound heterozygote; HDL‑C: HDL cholesterol; HE: Heterozygote, HO: Homozygote; LDL‑C: LDL cholesterol; M/F: Male/female; TC: Total cholesterol; 
TG: Tryglyceride.
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to either reduce the secretion of ANGPTL3 or 
to abolish its capacity to inhibit LPL in vitro 
[30]. The splice site mutation (c.1198+1G>T) in 
intron 6 was found to cause the partial retention 
of intron 6 in the mature mRNA [34]. 
Plasma levels of ANGPTL3 in familial 
combined hypolipidemia
The present authors’ group found that in carriers 
of two LOF alleles, no ANGPTL3 protein was 
detectable in plasma, while in carriers of one LOF 
allele, the mean level of plasma ANGPTL3 was 
approximately 40% of that found in control 
subjects [34]. These findings were confirmed in 
the study of Minicocci et al., which showed that 
homozygotes for LOF alleles (p.S17*) had no 
detectable ANGPTL3 protein in their plasma, 
while in heterozygotes, the level of ANGPTL3 
was reduced by 42% [36]. Overall, the carriers 
of two LOF alleles can be regarded as having a 
complete ANGPTL3 deficiency (ANGPTL3­/­), 
possibly as the result of defective secretion of the 
mutant truncated proteins or its rapid clearance 
from the plasma compartment. Such defective 
secretion may be due to accelerated intracellular 
degradation or defective synthesis of the mutant 
ANGPTL3 (due to the rapid degradation of the 
corresponding mRNA containing a premature 
termination codon). 
Plasma lipoproteins in familial 
combined hypolipidemia
n ApoB-containing lipoproteins
ApoB turnover studies conducted on selected 
members of family ‘F’ indicated marked 
changes of ApoB turnover [33]. The VLDL­
ApoB production rate was reduced by 70% in 
carriers of two mutant alleles (n = 2) and by 
40% in carriers of one mutant allele (n = 3). 
The LDL­ApoB fractional catabolic rate was 
increased by approximately 50% in carriers of 
two mutant alleles and approximately 40% in 
carriers of one mutant allele. These findings are 
consistent with the gene­dosage effect for VLDL 
production and LDL fractional catabolic rates, 
and provide an explanation for the codominant 
transmission of the low LDL­C and TG trait 
found in heterozygotes of family ‘F’. The link 
between these changes in the metabolism of 
ApoB­containing lipoproteins and ANGPTL3 
deficiency is not clearly understood. The 
decreased VLDL­ApoB production rate would 
imply some functional role of ANGPTL3 in 
the VLDL secretion pathway (including ApoB 
lipidation, intracellular assembly of VLDL 
particles and transfer of these particles from the 
lumen of the endoplasmic reticulum to the Golgi, 
among others). Under physiological conditions, 
ANGPTL3 might serve as a chaperone molecule 
functioning to protect ApoB from intracellular 
degradation, thus facilitating the assembly 
of a higher number of VLDL particles. In 
ANGPTL3 deficiency, this ‘protective’ effect 
on ApoB would be lost and fewer VLDL 
particles would be secreted. This appears to 
be an attractive hypothesis, even though the 
studies on hepatic TG secretion in ANGPTL3 
deficient mice do not appear to support this 
contention. In KK/Snk hypolipidemic mice, the 
in vivo secretion rate of plasma TG showed the 
tendency to be lower (by 15%) compared with 
the wild­type hypertriglyceridemic KK mice, but 
the difference was not significant [7]. A similar 
observation was made in ANGPTL3­null mice 
[10]. However, in vivo hepatic TG secretion in 
KK/Snk mice was found to be significantly 
reduced (by 25%) compared with that of 
normotriglyceridemic control mice [38].
VLDL turnover studies conducted in 
hypolipidemic KK/Snk mice revealed that 
these mice exhibited enhanced VLDL TG 
clearance compared with KK mice [7]. Similar 
turnover studies conducted in these mice on the 
ApoE knockout (KO) background showed that 
3H­labeled TGs and 125I­labeled VLDL ApoB 
were removed more rapidly from the circulation in 
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Figure 4. Percentage reduction of plasma lipids in carriers of loss-of-
function mutations in ANGPTL3. Mean percentage reduction of plasma lipids in 
carriers of one (n = 22) or two (n = 94) mutant alleles of the ANGPTL3 gene with 
respect to the lipid levels of noncarrier family members (n = 45). The mutant alleles 
are listed in Table 3. 
HDL-C: HDL cholesterol; LDL-C: LDL cholesterol; TC: Total cholesterol; 
TG: Triglyceride.
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the hypolipidemic KK/Snk ApoE KO compared 
with ApoE KO mice [38]. In addition, the oral 
fat­load test showed that in KK/Snk mice, the 
postprandial plasma TG increase was much lower 
than that found in control mice in the presence, 
as well as in the absence, of ApoE, a finding 
consistent with increased activity of LPL and 
hepatic lipase [38]. In view of these observations, 
one would expect an increased VLDL fractional 
catabolic rate and a faster postprandial removal 
of TG­rich lipoproteins to be present in humans 
with complete ANGPTL3 deficiency. 
The increased LDL­ApoB catabolic rate 
might be the result of unrestrained EL activity 
(due to the loss of the inhibitory effect of 
ANGPTL3). The hepatic overexpression of EL 
in mouse models with elevated levels of ApoB­
containing lipoproteins (ApoE deficient, LDL 
receptor deficient and human ApoB transgenic 
mice) resulted in markedly reduced VLDL/LDL 
cholesterol, phospholipids and ApoB levels, 
accompanied by a significant increase in LDL 
apolipoprotein and phospolipid catabolism [39].
n HDLs
Complete ANGPTL3 deficiency (ANGPTL3­/­) 
in humans was found to be associated not only 
with a striking reduction of plasma HDL­C and 
ApoA­I levels, but also with changes in HDL 
subclass distribution consisting of a striking 
reduction of LpAI and LpAI/AII particles (­70 
and ­30% respectively), a decreased level of 
pre­b­HDL and a reduced HDL size. In addition, 
the lecithin:cholesterolacyltransferase activity 
and the cholesterol esterification rate were found 
to be reduced or close to the lower limits of the 
normal range [34]. 
Some of the changes in HDL found in 
ANGPTL3­/­ subjects are probably due to the 
increased EL activity, as suggested by animal 
and human studies. Overexpression of EL in 
mice resulted in reduced plasma HDL levels 
and, conversely, EL KO mice showed significant 
increases in HDL levels [20]. In addition, EL 
overexpression in mice induced a dose­dependent 
increase in the fractional catabolic rate of HDL­
apolipoprotein and in renal ApoA­I catabolism 
[40], and produced an enhanced hepatic uptake 
of HDL­C through the SR­BI [41]. In humans, a 
negative correlation was found between HDL­C 
concentrations and both pre­ and post­heparin 
EL concentrations [42]. Furthermore, nuclear 
magnetic resonance ana lysis of plasma HDL 
revealed a negative association between post­
heparin EL concentrations and large HDL 
particles, and a positive association of EL mass 
with small HDL particles [42]. 
Further support for the role of increased EL 
activity on the HDL changes found in ANGPTL3­/­ 
subjects emerged from the resequencing of the 
LIPG gene (the gene encoding EL) in individuals 
with extreme levels of plasma HDL­C. Minor 
alleles of two variants (rs4299883 and rs2156552) 
of the LIPG gene reported to be highly associated 
with decreased HDL­C in the Global Lipid 
Genetics Consortium GWAS were tested for the 
association with HDL­C and HDL subtypes in 
subjects of the Framigham Heart Study [29]. The 
minor alleles of these variants were found to be 
associated with decreased HDL­C, HDL
2
, HDL
3
, 
HDL particle size and ApoA­I level. In keeping 
with these findings, these minor alleles were also 
associated with increased plasma EL [43].
The quantitative and qualitative changes in 
HDL­C observed in subjects with complete 
ANGPTL3 deficiency (ANGPTL3­/­) were also 
associated with a reduced capacity of their sera 
(depleted of ApoB­containing lipoproteins) to 
act as acceptors of cholesterol effluxed from cells 
through various pathways (ABCA1­, SR­BI­ and 
ABCG1­mediated pathways) [34]. This suggests 
that reverse cholesterol transport might be 
impaired in these individuals. In subjects with 
partial ANGPTL3 deficiency (ANGPTL3+/­), 
only the level of pre­b­HDL was found to be 
reduced. 
Consistent with this finding, the ApoB­
depleted sera of these subjects had a reduced 
capacity to act as acceptors of cholesterol effluxed 
via the ABCA1­mediated pathway. 
Familial combined hypolipidemia 
& atherosclerosis
Given the striking reduction of plasma HDL­C 
and ApoA­I, and the reduced capacity of the 
ApoB­depleted sera (a parameter found to show 
an inverse relationship with carotid intima­
media thickness and to be a strong predictor of 
coronary heart disease) [44], one would expect 
evident manifestations of preclinical/clinical 
atherosclerosis to be present in ANGPTL3­/­ 
subjects. On the other hand, these individuals 
have had a strikingly reduced plasma level of 
ApoB­containing lipoproteins (VLDL and 
LDL) since birth, a condition that might 
have counterbalanced any proatherogenic 
effect derived from low HDL and reduced 
HDL­mediated cholesterol efflux capacity. 
More specifically, no clinical overt mani­
festations of atherosclerotic cardio vascular disease 
Review | Calandra, Tarugi, Averna & Bertolini
www.futuremedicine.com 91future science group
was reported in ANGPTL3­/­ subjects of family ‘F’ 
(n = 4 adult subjects aged from 23 to 44 years) [33], 
of the Italian kindreds (n = 4 adult subjects aged 
from 53 to 85 years) [34] and of the Spanish kindreds 
(n = 2 adult subjects aged 39 and 41 years) [35]. In 
the large survey by Minicocci et al., carriers of two 
mutant ANGPTL3 alleles (n = 8 homozygotes with 
a mean age of 64.8 ± 14.2 years) did not show an 
increased risk for ischemic heart disease, compared 
with noncarriers of comparable age living in 
the same geographical district [36]. Therefore, 
the data available so far does not point to an 
increased risk of atherosclerotic cardiovascular 
disease in ANGPTL3­/­ subjects with combined 
hypolipidemia. The lack of a relationship between 
low HDL­C/reduced cholesterol efflux capacity of 
sera (as previously mentioned) and an increased 
susceptibility to atherosclerosis is probably due to 
the markedly reduced level of ApoB­containing 
lipoproteins found in these individuals. It is likely 
that the lifelong exposure to low levels of VLDL 
and LDL might counterbalance the putative 
‘proatherogenic’ effect related to low HDL­C. 
It seems interesting to consider these findings 
in the light of the observations made in the a 
KK/Snk/ApoE KO mice. Besides an extremely 
low level of HDL (associated with the absence of 
ApoE), these mice exhibited significant reductions 
in VLDL­TG, VLDL cholesterol and plasma 
ApoB compared with the ApoE KO mice. These 
mice developed threefold smaller atherogenic 
lesions in the aortic sinus compared with the 
control ApoE KO mice [38]. 
Familial combined hypolipidemia 
& liver disease
It is well established that in APOB­linked 
FHBL, severe fatty liver disease is present with a 
prevalence rate of approximately 20–30% [32]. In 
this condition, fatty liver is caused by an impaired 
secretion of ApoB­containing lipoproteins that 
leads to an accumulation of lipids (mainly TG) 
in the hepatocytes. Fatty liver has not been 
reported so far in subjects with ANGPTL3­/­ 
[33–35,37] and no increase in the prevalence of 
chronic liver disease was reported in carriers of 
two mutant ANGPTL3 alleles in the survey by 
Minicocci et al. [36]. 
Familial combined hypolipidemia 
& hematopoiesis
Studies in mice have suggested that ANGPTL3 is 
involved in the regulation of hematopoietic stem 
cell (HSC) activity. The addition of ANGPTL3 
to a culture of mouse bone marrow side 
population of CD45+Sca­1+ cells, together with 
saturating levels of other growth factors, resulted 
in a marked expansion of long­term mouse HSC 
number [45]. In line with this observation, HSCs 
were found to be decreased in number in Angptl3­/­ 
mice and wild­type HSCs transplanted into 
Angptl3­/­ mice exhibited impaired repopulation 
[46]. In Angptl3­/­ mice, the lack of production 
of ANGPTL3 by endothelial and stromal cells 
of the bone marrow significantly decreased the 
ability to support expansion of repopulating 
HSCs. In addition, the bone marrow of Angptl3­/­ 
was found to have a decreased number of 
granulocytes/monocytes progenitors (colony­
forming unit granulocytes/monocytes) and 
B lymphoid progenitors (colony­forming unit 
B progenitor cells) compared with bone marrow 
of wild­type mice [46]. Although there are no 
reports of the presence of hematological disorders 
in humans with complete ANGPTL3 deficiency, 
it would be interesting to know whether these 
subjects have subtle changes in blood cell 
number and whether they are more susceptible to 
developing some kind of hematological disorders 
during life.
Hypolipidemia in carriers of ANGPTL8 
gene variants
The observation in mice that ANGPTL8 
regulates TG and fatty acid metabolism by 
controlling the activation of ANGPTL3 [21] raises 
the possibility that in humans, LOF mutations 
of ANGPTL8 are the cause of a combined 
hypolipidemia phenotype similar to that found in 
homozygous/compound heterozygous carriers of 
LOF mutations of ANGPTL3. Quagliarini et al. 
investigated the effect of a common NS sequence 
variant of ANGPTL8 (c.194C>T, rs2278426 
resulting in tryptophan for arginine substitution, 
Arg59Trp or R59W) on plasma lipoproteins 
among the participants of the DHS trial [21]. This 
variant was found to be more common among 
Hispanics (MAF = 26%) and African–Americans 
(MAF = 18%) than European–Americans 
(MAF = 5%). In African–Americans and 
Hispanics, Arg59Trp was associated with 
reduced LDL­C and HDL­C levels without 
changes in TG levels. This association was 
replicated in African–American participants in 
the ARIC study. In the European–Americans 
of ARIC, the Arg59Trp variant was associated 
with significantly lower levels of HDL­C, but 
not LDL­C. Taken together, these observations 
indicate that putative LOF variants of ANGPTL8 
may induce a hypolipidemia phenotype, which 
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appears to be different from that observed in 
carriers of LOF mutations of ANGPTL3. Only 
the identification of individuals carrying two 
null ANGPTL8 alleles (ANGPTL8­/­ individuals) 
will clarify this issue.
Conclusion
Almost 10 years have elapsed since the report of 
a severe recessive form of hypotriglyceridemia 
in a mouse strain carrying a LOF mutation 
of the ANGPTL3 gene, expected to lead to 
a complete ANGPTL3 deficiency. A severe 
hypolipidemia characterized by reduced levels 
of both TG and TC was subsequently found 
in ANGPTL3 KO mice. In vivo and in vitro 
studies have demonstrated that ANGPTL3 acts 
as an inhibitor of both LPL and EL. GWAS in 
humans indicated an association of ANGPTL3 
locus variants with plasma TG. The resequencing 
of the ANGPTL3 gene in populations demon­
strated an enrichment of LOF mutations in 
individuals in the lowest quartile of plasma TGs. 
Recently, the genomic investigation of a large 
family with FHBL, not linked to the APOB or 
PCSK9 gene, led to the identification of LOF 
mutations in the ANGPTL3 gene as the cause of 
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ANGPTL3 & lipoprotein metabolism in mice & humans
  Early studies in mice had demonstrated that loss-of-function mutations of ANGPTL3 were associated with a severe hypolipidemia 
affecting all plasma lipoprotein classes, specifically the triglyceride-rich lipoproteins. ANGPTL3 was found to inhibit lipoprotein lipase 
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Activation of ANGPTL3 by ANGPTL8, a new member of ANGPTL family
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activates ANGPTL3 by facilitating its proteolytic cleavage and the release of the N-terminal domain, which is responsible for the 
inhibition of lipoprotein lipase and endothelial lipase.
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  In mice and humans, the plasma level of ANGPTL3 appears to be directly correlated to that of plasma HDL cholesterol (HDL-C).
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  Genome-wide association studies have documented an association of single nucleotide polymorphisms located close to the ANGPTL3 
locus and a reduction of plasma triglyceride. Rare loss-of-function mutations of the ANGPTL3 gene were found in individuals with low 
plasma triglycerides in population studies.
ANGPTL3 & familial combined hypolipidemia
  Loss-of-function mutations in the ANGPTL3 gene in the homozygous/compound heterozygous state were found to be the cause of a 
marked reduction of all plasma lipoprotein classes, a condition designated familial combined hypolipidemia. This disorder does not 
seem to be associated with tangible clinical manifestations. Heterozygous carriers of these mutations appear to have reduced plasma 
LDL cholesterol and triglyceride levels.
Plasma level of ANGPTL3 in familial combined hypolipidemia
  ANGPTL3 protein was not detectable in plasma of subjects with familial combined hypolipidemia, indicating that the presence of two 
loss-of-function alleles leads to a complete ANGPTL3 deficiency.
Plasma lipoproteins in familial combined hypolipidemia
  In vivo kinetic studies showed a marked reduction of VLDL-ApoB production rate and an increased LDL-ApoB catabolic rate in carriers 
of two mutant ANGPTL3 alleles. The subjects have marked changes in plasma HDL subclasses characterized specifically by a reduction 
of HDL size and of the pre-b HDL particles.
  ApoB-depleted sera of these subjects have a reduced capacity to act as acceptors of cholesterol released from the cells in vitro through 
the various efflux pathways. This suggests a defect in the early steps of reverse cholesterol transport. 
Familial combined hypolipidemia & atherosclerosis
  Despite the striking reduction of plasma HDL-C and ApoA-I, no premature atherosclerosis has been reported so far in individuals with 
familial combined hypolipidemia.
Familial combined hypolipidemia & liver disease
  Despite a reduction of plasma ApoB-containing lipoproteins similar to that observed in familial hypobetalipoproteinemia, fatty liver 
disease has not been reported so far in subjects with familial combined hypolipidemia.
Familial combined hypolipidemia & hematopoiesis
  In the bone marrow of ANGPTL3-/- mice, the number of hematopoietic stem cells and that of granulocyte/monocyte progenitors, and 
B-lymphoid progenitors, was found to be reduced. A careful monitoring of the blood cell count is recommended in subjects with 
familial combined hypolipidemia.
Hypolipidemia in carriers of ANGPTL8 gene variants
  Sequencing of the ANGPTL8 gene in populations has led to the discovery of a common sequence variant (Arg59Trp) that was found to 
be associated, in the heterozygous state, with lower plasma LDL cholesterol and HDL-C levels.
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a severe hypolipidemia involving all lipoprotein 
classes (VLDL, LDL and HDL). This study 
prompted the resequencing of the ANGPTL3 
gene in individuals with unexplained FHBL, 
showing a combined hypolipidemia phenotype. 
These surveys led to the identification of several 
individuals homozygous/compound heterozygous 
for LOF mutations causing complete ANGPTL3 
deficiency. Familial combined hypolipidemia is 
transmitted as a recessive disorder. However, 
preliminary evidence indicates that heterozygotes 
may have reduced plasma LDL­C and TG, 
suggesting that this trait has a codominant 
transmission. In vivo kinetic studies indicated 
that individuals carrying two mutant ANGPTL3 
alleles have a reduced VLDL­ApoB production 
rate and an increased LDL­ApoB catabolic rate. 
On the other hand, these individuals also have 
significant changes in HDL subpopulations and 
a reduced capacity of their sera to act as acceptors 
of cholesterol eff lux from the cells in vitro, 
suggesting an impaired reverse cholesterol 
transport. Familial combined hypolipidemia 
does not seem to be associated with overt clinical 
manifestations. Recent studies have indicated that 
ANGPTL3 is activated by ANGPTL8, a novel 
member of the angiopoietin­like protein family. 
In some populations, a common mis sense variant 
of ANGPTL8 was found to be associated with 
reduced plasma levels of some lipoprotein classes. 
Future perspective
The recent finding that complete ANGPTL3 
deficiency is the cause of combined familial 
hypolipidemia raises several questions concerning 
the biochemical mechanism underlying this lipid 
disorder, the possible long­term effect of this 
hypolipidemia and the role of ANGPTL3 as a 
possible target for hypolipidemic drugs. 
With regard to the mechanism, it would 
be interesting to know whether the role of 
ANGPTL3 is confined to the inhibition of LPL 
and EL, or also involves the assembly and secretion 
of ApoB­containing lipoproteins in the liver. It 
is possible that ANGPTL3 acts as a chaperone 
molecule that protects ApoB from intracellular 
degradation before its incorporation into nascent 
lipoprotein particles. Another key issue is whether 
the unrestrained activity of EL expected to occur 
in complete ANGPTL3 deficiency has a negative 
effect on the functionality of HDL with regard to 
the protection against atherosclerosis. 
The identif ication of individuals with 
complete ANGPTL3 deficiency will set the stage 
for a number of clinical investigations aimed at 
defining whether the combined hypolipidemia 
predisposes to complications, such as premature 
atherosclerosis (in view of the reduced level 
and the structural changes of HDL), fatty 
liver diseases (in view of the possible defect in 
VLDL production), defects in steroid hormone 
production (in view of the reduced availability 
of the LDL­ and HDL­derived cholesterol in the 
steroidogenic tissues) or hematological disorders 
(in view of the stimulatory effect of ANGPTL3 
on hematopoietic stem cells in the bone marrow).
Finally, the observation that individuals 
heterozygous for LOF mutations with partial 
ANGPTL3 deficiency have reduced levels 
of LDL­C and TG may prompt the search 
for therapeutic strategies aimed at reducing 
the inhibitory effect of ANGPTL3 on LPL. 
Partial inhibition of ANGPTL3 is expected to 
be associated with an increased catabolism of 
TG­rich lipoproteins. 
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